Navigation Links
Vical Licensee AnGes MG Announces Positive Results of Phase 3,Angiogenesis Trial in Japan

SAN DIEGO, June 18, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that the company's licensee, AnGes MG, Inc. reported positive results following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of an angiogenesis product candidate using Vical's DNA delivery technology. Based on the findings that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment, an Independent Data Monitoring Committee (IDMC) recommended stopping the trial early to prevent potential ethical issues against the placebo group subjects. AnGes is ending the trial and preparing to file an application for Japanese marketing approval.

"The successful Phase 3 results from our Japanese licensee position the AnGes product candidate to be the first approved for human use based on our DNA delivery technology and provide proof of concept for DNA delivery in the treatment of disease," said Vijay B. Samant, President and Chief Executive Officer of Vical. "This novel approach has the potential to address an important, unserved medical need in a significant commercial market. We look forward to further updates from AnGes as they advance through the regulatory approval process."

The treatment uses Vical technology to deliver a gene encoding Hepatocyte Growth Factor (HGF), a human protein that causes angiogenesis (growth of blood vessels) in areas of ischemia (restricted blood flow). In the trial, 40 subjects with critical limb ischemia (advanced peripheral arterial disease) were evaluated for efficacy. The primary endpoints, improvement of rest pain ((VAS (Visual Analog Scale)) or ischemic ulcer size, at 12 weeks post dosing, showed 30.8% improvement in the placebo group and 70.4% improvement in the treatment group, a statistically significant difference (p=0.014).

The following English
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
2. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
3. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
4. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/23/2014)... 23, 2014 Rising health ... and increasing number of foreign and domestic players in ... India   The ... most high growth potential markets worldwide due to multiple ... among the youth, changing food consumption patterns, increasing diabetic ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
(Date:9/23/2014)... 23, 2014   COTA, Inc. today announced ... million Series A funding round led by Horizon Healthcare ... the first big data platform designed by practicing oncologists ... for cancer care in support of healthcare,s new value-based ... expand development of the COTA platform, hire biostatisticians, outcome ...
Breaking Medicine Technology:India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 2India Probiotic Market Pegged to Grow at Around 20% by 2019, Says TechSci Research 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 2COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 3COTA Closes $3.7M of Planned $7M Series A Funding Round to Transform Cancer Outcomes and Reimbursement 4
...  ZHUHAI, China, Oct. 24, 2011 ... a leading global manufacturer of electronic medical devices ... worldwide technology licensing agreement and the launch of ...  new generation of modular patient monitors. The agreement ...
... Mont., Oct. 24, 2011 Bacterin International ... leader in the development of revolutionary bone graft material and ... at the Singular Research,s Sixth Annual ,Best of the Uncovereds, ... Boulevard Hotel in Los Angeles, California. Bacterin,s chairman ...
Cached Medicine Technology:Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 2Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 3Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 4Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 5Guangdong Biolight Meditech Co., Ltd. Announces the Launch of Its Modular Patient Monitors with Masimo rainbow SET Pulse CO-Oximetry Technology 6Bacterin to Present at Sixth Annual Singular Research 'Best of the Uncovereds' Conference on October 26, 2011 2
(Date:9/23/2014)... Sinica, the preeminent academic institution in the Republic ... agreement to develop a unique educational and scientific ... to translate innovative technologies and commercially relevant discoveries ... Sept.12 in Taipei by Harris Lewin, vice chancellor ... Wong of Academia Sinica. The program will be ...
(Date:9/23/2014)... TX (PRWEB) September 23, 2014 As ... taken before making a purchase. It’s difficult to trust ... it’s easy for them to manipulate their customers into ... this dilemma, but they tend to lack in depth ... Health Reports was founded to fix this issue ...
(Date:9/23/2014)... used to diagnose lung cancer may not be as reliable ... a new analysis says. One noninvasive way of ... as functional imaging. For lung cancer, a specific type of ... authors. Cancerous tumors generally look different on FDG-PET images ... have cancer, according to background information in the study. But, ...
(Date:9/23/2014)... What information do patients need ... Forum (NQF) released a report ( http://bit.ly/1DwekE9 ), ... infographic ( http://bit.ly/1tX3lzA ) resulting from an in-depth ... patients define affordability, and what information and changes ... possible healthcare at the lowest possible cost. ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... unapproved prescription drugs is growing, so doctors need ... Food and Drug Administration warned Tuesday. In ... so widespread that it has launched a program ... and administrators about proper drug purchasing procedures. The ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Consumer Health Reports Debuts Revolutionary Review Website 2Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:Finding Affordable Care: Asking the Right Question is Key 2
... Alan Mozes HealthDay Reporter , TUESDAY, Dec. 20 ... wriggling) competition in cleaning troublesome wounds: maggots. To the ... suggests that bagging up live, sterile fly larvae in tightly ... be a quick, safe and effective way to clear ...
... Gordon HealthDay Reporter , TUESDAY, Dec. 20 (HealthDay ... a doctor should decide if complications are severe enough to ... (ADA) says. In a new position statement published in ... advises against blanket bans or restrictions. Instead, it recommends that ...
... accounts for the majority of all thyroid malignancies, which primarily ... nodes in the neck in these cancer patients may help ... thyroid cancer metastasizes, lymph nodes in the neck may be ... not be detected by ultrasounds done before surgery to remove ...
... 20 (HealthDay News) -- Increasing concentrations of two ... samples collected in the Great Lakes region between ... The chemicals are used to reduce flammability in ... and polyurethane foams. They are 2-ethylhexyl tetrabromobenzoate [TBB] ...
... 20, 2011Women who are at risk for breast cancer may ... has found. The majority of women with hereditary breast ... or BRCA2 genes, which normally suppress the growth of breast ... at St. Michael,s Hospital, said his research team was surprised ...
... HealthDay Reporter , MONDAY, Dec. 19 (HealthDay News) -- ... likely to develop inflammatory bowel disease such as Crohn,s disease ... according to a new long-term study. Endometriosis ... grows outside of the uterus. Symptoms include abdominal pain, ...
Cached Medicine News:Health News:Maggots Quickly Clean Up Wounds, Study Shows 2Health News:Maggots Quickly Clean Up Wounds, Study Shows 3Health News:Driving Isn't An Issue for Most People With Diabetes 2Health News:Driving Isn't An Issue for Most People With Diabetes 3Health News:Removal of lymph nodes during surgery for thyroid cancer may be beneficial 2Health News:Removal of lymph nodes during surgery for thyroid cancer may be beneficial 3Health News:Buildup of Newer Flame Retardants Concerns Scientists 2Health News:Breast cancer and heart disease may have common roots 2Health News:Endometriosis Tied to Higher Risk of Crohn's, Colitis 2
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Terumo's Outlook offers superior torque and precision control. It's patient-friendly, high torque design makes it the catheter of choice for demanding angiography....
Femoral selective catheter. Catheter material used is polyurethane (TRICOR). Guidewire campatibility is 0.038". Packaging 5/Box....
Cordis DUCOR Catheters are available in a broad variety of French sizes and configurations. These catheters combine an atraumatic tip with either a braided or non-braided body....
Medicine Products: